(VVOS) Vivos Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92859E1082

The Vivos Method, VivoScore Program, Appliances, Treatments, Services

VVOS EPS (Earnings per Share)

EPS (Earnings per Share) of VVOS over the last years for every Quarter: "2020-03": -5.17, "2020-06": -2.83, "2020-09": -3.63, "2020-12": -11.32, "2021-03": -4.67, "2021-06": -4.87, "2021-09": -6.55, "2021-12": -22, "2022-03": -4.95, "2022-09": -6.43, "2022-12": -7.93, "2023-03": 4.82, "2023-06": -4.62, "2023-09": -1.75, "2023-12": -2.32, "2024-03": -1.63, "2024-06": -0.6, "2024-09": -0.4, "2024-12": -0.48, "2025-03": -0.45,

VVOS Revenue

Revenue of VVOS over the last years for every Quarter: 2020-03: 3.196507, 2020-06: 3.271188, 2020-09: 3.291602, 2020-12: 3.30694, 2021-03: 3.447881, 2021-06: 4.496756, 2021-09: 4.545943, 2021-12: 4.39442, 2022-03: 3.46, 2022-09: 4.246, 2022-12: 3.95, 2023-03: 3.857, 2023-06: 3.395, 2023-09: 3.301, 2023-12: 3.248, 2024-03: 3.419, 2024-06: 4.054, 2024-09: 3.86, 2024-12: 3.698, 2025-03: 3.016,

Description: VVOS Vivos Therapeutics

Vivos Therapeutics, Inc. is a medical technology company that has developed a groundbreaking treatment approach for dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring. The companys flagship product, The Vivos Method, is a non-invasive, multi-disciplinary treatment modality that offers a revolutionary alternative to traditional surgical and pharmaceutical interventions. By leveraging a network of licensed professionals, primarily general dentists in the US and Canada, Vivos Therapeutics is well-positioned to capitalize on the growing demand for effective and non-invasive treatments for these prevalent conditions.

The companys business model is centered around the sale of its proprietary appliances and related treatments and services to healthcare professionals. Additionally, Vivos Therapeutics offers the VivoScore Program, a screening and home sleep test for adults and children, which provides a valuable diagnostic tool for healthcare professionals and expands the companys revenue streams. With its headquarters in Littleton, Colorado, Vivos Therapeutics has established itself as a key player in the healthcare technology sector, with a strong foundation for growth and expansion.

From a technical analysis perspective, VVOS stock has experienced significant volatility, with a 52-week high of $5.95 and a low of $1.95. The current price of $2.09 is below its short-term moving averages (SMA20: $2.68, SMA50: $2.76), indicating a potential bearish trend. However, the Average True Range (ATR) of 0.23 (11.10%) suggests that the stock is still relatively active, with potential for price movements. Given the current technical indicators, it is likely that VVOS will continue to experience a period of consolidation before breaking out or breaking down.

Fundamentally, Vivos Therapeutics has a relatively small market capitalization of $18.02M USD, which may limit its ability to attract large institutional investors. The absence of a price-to-earnings (P/E) ratio and a negative return on equity (RoE) of -197.55% indicate that the company is currently unprofitable. However, this is not uncommon for growth-stage companies in the healthcare technology sector. As the company continues to grow its revenue and expand its customer base, it is likely that VVOS will eventually achieve profitability, which could lead to a significant increase in its stock price.

Forecasting the future performance of VVOS stock requires a combination of technical and fundamental analysis. Based on the current technical indicators, it is likely that the stock will continue to experience a period of consolidation in the near term. However, if Vivos Therapeutics is able to achieve significant growth in its revenue and customer base, it is possible that the stock could break out above its current resistance levels, potentially reaching $3.25 (SMA200) or higher. Conversely, if the company fails to achieve its growth objectives, the stock could continue to decline, potentially testing its 52-week low of $1.95. A key catalyst for VVOS stock will be the companys ability to demonstrate the efficacy and safety of its treatment modalities, as well as its ability to expand its customer base and achieve profitability.

Additional Sources for VVOS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

VVOS Stock Overview

Market Cap in USD 30m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Equipment
IPO / Inception 2020-12-11

VVOS Stock Ratings

Growth Rating -69.1
Fundamental -51.1
Dividend Rating 0.0
Rel. Strength 129
Analysts 4 of 5
Fair Price Momentum 2.28 USD
Fair Price DCF -

VVOS Dividends

Currently no dividends paid

VVOS Growth Ratios

Growth Correlation 3m 30.5%
Growth Correlation 12m 11.6%
Growth Correlation 5y -95.4%
CAGR 5y -56.32%
CAGR/Max DD 5y -0.57
Sharpe Ratio 12m -0.89
Alpha 99.41
Beta 1.653
Volatility 158.24%
Current Volume 801.1k
Average Volume 20d 222k
Stop Loss 4.7 (-8.2%)
What is the price of VVOS shares?
As of July 09, 2025, the stock is trading at USD 5.12 with a total of 801,060 shares traded.
Over the past week, the price has changed by +32.30%, over one month by +139.25%, over three months by +129.60% and over the past year by +118.34%.
Is Vivos Therapeutics a good stock to buy?
No, based on ValueRay´s Fundamental Analyses, Vivos Therapeutics (NASDAQ:VVOS) is currently (July 2025) a stock to sell. It has a ValueRay Fundamental Rating of -51.10 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VVOS is around 2.28 USD . This means that VVOS is currently overvalued and has a potential downside of -55.47%.
Is VVOS a buy, sell or hold?
Vivos Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy VVOS.
  • Strong Buy: 1
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecasts for VVOS share price target?
According to our own proprietary Forecast Model, VVOS Vivos Therapeutics will be worth about 2.7 in July 2026. The stock is currently trading at 5.12. This means that the stock has a potential downside of -46.48%.
Issuer Target Up/Down from current
Wallstreet Target Price 4.2 -17.4%
Analysts Target Price 4.2 -17.4%
ValueRay Target Price 2.7 -46.5%